Country for PR: United Kingdom
Contributor: PR Newswire Europe
Thursday, April 09 2020 - 22:06
Excelra Releases COVID-19 Drug Repurposing Database to Support Global Drug Development Efforts Against Novel Coronavirus
HYDERABAD, India, April 9, 2020 /PRNewswire-AsiaNet/ --

    Excelra, a leading global data and analytics company, today announced the 
release of the COVID-19 Drug Repurposing Database 
( The 
'open-access' database presents a compilation of 'previously approved' small 
molecules and biologics with known preclinical, pharmacokinetic, 
pharmacodynamic, and toxicity profiles that can rapidly enter either Phase 2 or 
3 clinical trials on fast track basis for COVID-19. In addition, the database 
also includes information on promising drug candidates that are in various 
'clinical, pre-clinical and experimental' stages of drug discovery and 
development for COVID-19.
    Alluding to this wealth of information, Dr. Nandu Gattu, Senior Vice 
President, Pharma Analytics, Excelra said, "The COVID-19 DR database is a 
compilation of crucial data that is dispersed across numerous publications, 
reports, databases and knowledge-repositories along with referenced literature 
covering the drug, disease, target, and mechanism of action. Our endeavour is 
in support to the ongoing global scientific efforts for identifying safe and 
effective therapeutic options to treat the novel coronavirus disease." 
    Drug Repurposing at Excelra is powered by their Global Repurposing 
Integrated Platform (GRIP) that combines proprietary repurposing databases, 
algorithms, analytics tools and a visualization engine. The GRIP database is 
built by amassing vast chemical data, biological data and clinical data which 
together contribute to more than 10 million associations among 
'drug-disease-target' triads.
    About Excelra:

    Excelra's data and analytics solutions empower innovation in life sciences 
across the value chain from discovery to market. The Excelra Edge comes from a 
seamless amalgamation of proprietary curated data assets, deep domain expertise 
and data science. The company's multifaceted teams harmonize and analyse large 
volumes of disparate unstructured data using cutting-edge technologies. We 
galvanize data-driven decisions to unlock operational efficiencies to 
accelerate drug discovery and development. Over the past 18 years, Excelra has 
been the preferred data and analytics partner to over 150 global clients 
including 15 of the top 20 large Pharma companies.

    Access COVID-19 Drug Repurposing Database:

    Contact Information: 
    Dorothy Paul – Director Marketing 
    Tel: +91-9908130236 

    Source: Excelra Knowledge Solutions Pvt Ltd